Back to today’s briefing

Story perspectives

FDA Fast-Tracks Lung Cancer Treatment with Promising Results

5/15/2025

46 9

Summary

FDA Fast-Tracks Cancer Treatment

The FDA has fast-tracked the approval of telisotuzumab vedotin (Emrelis) for adults battling advanced non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein levels. This decision stems from promising results in the LUMINOSITY trial, which revealed a 35% response rate and a median response duration of 7.2 months, offering hope to patients after previous treatments.

Summary

Cytalux Enhances Surgeries

Cytalux, the groundbreaking FDA-approved optical imaging agent, transforms lung cancer surgeries by illuminating cancer cells, empowering surgeons with enhanced precision. Dr. Hamid Mumtaz from AdventHealth emphasizes its promise to lower recurrence rates, currently at a staggering 55%, by enabling more confident resections. This innovation marks a pivotal leap forward in the fight against lung cancer.

1 of 2

FDA Fast-Tracks Cancer Treatment

The FDA has fast-tracked the approval of telisotuzumab vedotin (Emrelis) for adults battling advanced non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein levels. This decision stems from promising results in the LUMINOSITY trial, which revealed a 35% response rate and a median response duration of 7.2 months, offering hope to patients after previous treatments.

1 / 2